Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cutaneous T-Cell Lymphoma: Disease, Diagnosis, and Therapy

Similar presentations


Presentation on theme: "Cutaneous T-Cell Lymphoma: Disease, Diagnosis, and Therapy"— Presentation transcript:

1 Cutaneous T-Cell Lymphoma: Disease, Diagnosis, and Therapy

2 What Is Cutaneous T-Cell Lymphoma (CTCL)?

3 MF and SS/L-CTCL Subtypes

4 CTCL Affects a Considerable Population, and Incidence Is Increasing

5 Etiology and Risk Factors for CTCL

6 WHO Classification 2016: T-Cell Lymphoma

7 Pathogenesis

8 Somatic Single Nucleotide Variants (SSNVs) 75% C > T Transitions

9 Mutations in Signal Transduction Pathways

10 Cytokine Expression and Cellular Changes in Early and Late Stages of MF/SS

11 Th1/Th2 Dichotomy in Progressive CTCL

12 Functional Polarization Suppresses Normal T-Cell Function and Induces Autocrine Proliferation

13 Development of T-Cell Clonality Assessment

14 PROCLIPI Study for MF and SS

15 PROCLIPI Study: Stage at Diagnosis (n = 693)

16 Clinical Features of MF

17 5-Year Survival Rates for MF and SS

18 Clinical Spectrum: Stages IA and IB

19 Clinical Spectrum: Stage IB

20 Patches, Plaques, and Tumors Occurring Simultaneously

21 Advanced-Stage MF

22 Key Histologic Features of MF: Histopathology

23 Key Histologic Features of MF: Immunophenotype

24 Histologic Features of MF

25 Folliculotropic MF

26 Distinct Subtypes of MF

27 Examples of MF Subtypes

28 Differential Diagnosis of MF

29 Defining Early MF

30 Initial Diagnosis of Suspected MF/SS

31 TNMB Classification of MF/SS: Current Recommendations

32 Clinical Staging of MF and SS: Current Recommendations

33 CTCL Is Associated With Significantly Reduced QoL

34 Patient-Reported Impact of CTCL

35 Goals of Therapy for Patients With CTCL in 2018

36 Due to Its Heterogeneity, CTCL Has No Single, Common Management Plan

37 Current Treatment Strategies for MF/SS Are Based on Disease Stage

38 EORTC Recommendations for First-Line Treatment of MF (Stages IA, IB, and IIA)

39 ESMO Recommendations for Treatment of MF

40 Interferon-α and Bexarotene

41 Interferon-α Mono- and Combination Therapy in Cutaneous Lymphomas

42 Combinations

43 Conclusions

44 Abbreviations

45 Abbreviations (cont)

46 Abbreviations (cont)


Download ppt "Cutaneous T-Cell Lymphoma: Disease, Diagnosis, and Therapy"

Similar presentations


Ads by Google